Poplar Therapeutics
Developing a new class of anti-IgE therapy to treat food allergy and other atopic conditions
$45MSeries A+
Role not disclosedSO
SR One
Activity from announced rounds
Activity in this selectionSeries A
- Rounds participated in
- 3
- Confirmed lead rounds
- — 3 roles undisclosed
- New companies
- 2 First participation on record · 1 follow-on
- Funding in participating rounds
- $295M 3 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
3 in this selectionAirNexis Therapeutics
AirNexis Therapeutics develops medicines for pulmonary diseases, led by the investigational COPD candidate AN01.
$200MSeries A
Role not disclosedPoplar Therapeutics
Developing a new class of anti-IgE therapy to treat food allergy and other atopic conditions
$50MSeries A
Role not disclosed